A new molecule is emerging: Retatrutide A triple agonist targeting: GLP-1 GIP Glucagon Early clinical data suggests: Up to ~30% weight loss This could represent the next major leap in obesity treatment
Lilly used this approach with tirzepatide
At Sarayu Clinics, our expert team administers these treatments safely, ensuring minimal downtime and noticeable improvements in skin health
Patients with early T2D (mean diabetes duration 34 years) managed on diet and exercise only were studied in SUSTAIN 1 and PIONEER 1 ( 1c range ( Table 1 )
Using sterile equipment, disinfecting vial stoppers with alcohol before each puncture, minimizing unnecessary vial access, and refrigerating the peptide promptly after use all help support good laboratory handling practices
By activating the receptors for both GIP and GLP-1, it helps improve insulin sensitivity, slows down digestion, and reduces hunger, leading to a feeling of fullness after eating smaller portions